A clinical view on the development of technology-based tools in managing Parkinson's disease

Movement Disorders

Volumn 31, Issue 9, 2016, Pages 1263-1271

  Maetzler, Walter ^a,b   Klucken, Jochen ^c   Horne, Malcolm ^d,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Neurology Department   (Australia)

Author keywords

Framework; objective assessment; treatment; wearable sensor

Indexed keywords

ABNORMAL POSTURE; AKINESIA; ARTICLE; BIOMECHANICS; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DYSKINESIA; GAIT DISORDER; HUMAN; MEDICAL TECHNOLOGY; MOTOR DYSFUNCTION; NERVOUS SYSTEM PARAMETERS; NEUROLOGIC DISEASE ASSESSMENT; PARKINSON DISEASE; PHYSICAL INACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SENSOR; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84985962989     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26673     Document Type: Article

References (87)

1. Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr 1961;73:787–788.
2. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374–379.
3. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(21 Suppl 4):S1–S136.
4. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22:41–47.
5. National Institute for Health and Clinical Excellence (NICE). NICE Clinical Guideline 35: Parkinson's disease—diagnosis and management in primary and secondary care (full guideline). 2006. Available at: http://www.nice.org.uk/CG35. Accessed 11 July 2012.
6. Katz M, Kilbane C, Rosengard J, Alterman RL, Tagliati M. Referring patients for deep brain stimulation: an improving practice. Arch Neurol 2011;68:1027–1032.
7. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610–622.
8. Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord 2013;28:1628–1637.
9. Maetzler W, Rochester L. Body-worn sensors—the brave new world of clinical measurement? Mov Disord 2015;30:1203–1205.
10. Ossig C, Antonini A, Buhmann C, et al. Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. J Neural Transm 2015;123:57–64.
11. Pasluosta CF, Gassner H, Winkler J, Klucken J, Eskofier BM. An emerging era in the management of Parkinson's disease: wearable technologies and the Internet of things. IEEE J Biomed Heal informatics 2015;19:1873–1881.
12. Sánchez-Ferro A, Elshehabi M, Godinho C, et al. New technologies for the assessment of Parkinson's disease from 2005 to 2015: a systematic review of a decade of innovation. This Seriew; in revision.
13. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes in adults: management | Guidance and guidelines. London: NICE; 2015.
14. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–520.
15. van Uem J, Marinus J, Canning C, et al. Health-related quality of life in patients with Parkinson's disease—a systematic review based on the ICF model. Neurosci BiobehavRev 2016;61:26–34.
16. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord 2007;22:1528–1537.
17. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896–908.
18. Post B, Merkus MP, de Haan RJ, Speelman JD. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007;22:1839–1851; quiz, 1988.
19. Soh SE, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2011;17:1–9.
20. Horne M, McGregor S, Lynch P, Zoellner Y. Objective data In Parkinson's disease therapy management—a retrospective analysis of the Parkinson's Kinetigraph (Pkg) Database. Value Health 2015;18:A685.
21. Horne MK, McGregor S, Bergquist F. An objective fluctuation score for Parkinson's disease. PLoS One 2015;10:e0124522.
22. Muslimovic D, Filipkowski DE, Riley DE, et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008;70:2241–47.
23. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58–64.
24. Mera TO, Burack MA, Giuffrida JP. Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology. Proc Annu Int Conf IEEE Eng Med Biol Soc EMBS 2012;2012:154–157.
25. Heldman DA, Filipkowski DE, Riley DE, et al. Automated motion sensor quantification of gait and lower extremity bradykinesia. Conf Proc IEEE Eng Med Biol Soc 2012;2012:1956–1959.
26. Heldman DA, Giuffrida JP, Chen R, et al. The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures. Mov Disord 2011;26:1859–1863.
27. Griffiths RI, Kotschet K, Arfon S, et al. Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. J Parkinsons Dis 2012;2:47–55.
28. Fox SH, Lang AE. Levodopa-related motor complications—phenomenology. Mov Disord 2008;23(Suppl 3):S509–S514.
29. Péchevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956–963.
30. Hechtner MC, Vogt T, Zöllner Y, et al. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 2014;20:969–974.
31. Manson A, Stirpe P, Schrag A. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2012;2:189–198.
32. Fox SH, Katzenschlager R, Lim S-Y, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2–S41.
33. Lopane G, Mellone S, Chiari L, Cortelli P, Calandra-Buonaura G, Contin M. Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease. Mov Disord 2015;30:1267–1271.
34. Ramsperger R, Meckler S, Heger T, et al. Continuous leg dyskinesia assessment in Parkinson's disease—clinical validity and ecological effect. Parkinsonism Relat Disord 2016;26:41–46.
35. Pulliam CL, Burack MA, Heldman DA, Giuffrida JP, Mera TO. Motion sensor dyskinesia assessment during activities of daily living. J Parkinsons Dis 2014;4:609–615.
36. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004;19:1409–1413.
37. Papapetropoulos SS. Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. CNS Neurosci Ther 2012;18:380–387.
38. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001;19:1013–1038.
39. Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80:800–809.
40. Stocchi F, Antonini A, Barone P, et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 2014;20:204–211.
41. Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord 2015;30:1451–1460.
42. Chang FC, Kwan V, van der Poorten D, et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci 2016;25:41–45.
43. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol 2010;63:257–266.
44. Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord 2008;23:359–365.
45. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502–1507.
46. Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G. Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 2008;23:1420–1427.
47. Elshehabi M, Maier KS, Hasmann SE, et al. Limited effect of dopaminergic medication on straight walking and turning in early to moderate Parkinson's disease during single and dual tasking. Front Aging Neurosci 2016;8:4.
48. McNeely ME, Duncan RP, Earhart GM. Medication improves balance and complex gait performance in Parkinson disease. Gait Posture 2012;36:144–148.
49. Maetzler W, Nieuwhof F, Hasmann SE, Bloem BR. Emerging therapies for gait disability and balance impairment: promises and pitfalls. Mov Disord 2013;28:1576–1586.
50. Lord S, Baker K, Nieuwboer A, Burn D, Rochester L. Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction? J Neurol 2011;258:566–572.
51. McNeely ME, Earhart GM. The effects of medication on turning in people with Parkinson Disease with and without freezing of gait. J Parkinsons Dis 2011;1:259–270.
52. Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 1998;13:428–437.
53. Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:249–258.
54. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010;75:1263–1269.
55. Klamroth S, Steib S, Devan S, Pfeifer K. Effects of exercise therapy on postural instability in Parkinson disease: a meta-analysis. J Neurol Phys Ther 2016;40:3–14.
56. Rampp A, Barth J, Schülein S, Gaßmann K-G, Klucken J, Eskofier BM. Inertial sensor-based stride parameter calculation from gait sequences in geriatric patients. IEEE Trans Biomed Eng 2015;62:1089–1097.
57. Weiss A, Sharifi S, Plotnik M, vanVugt JP, Giladi N, Hausdorff JM. Toward automated, at-home assessment of mobility among patients with Parkinson disease, using a body-worn accelerometer. Neurorehabil Neural Repair 2011;25:810–818.
58. Mariani B, Hoskovec C, Rochat S, Büla C, Penders J, Aminian K. 3D gait assessment in young and elderly subjects using foot-worn inertial sensors. J Biomech 2010;43:2999–3006.
59. Horak FB, Mancini M. Objective biomarkers of balance and gait for Parkinson's disease using body-worn sensors. Mov Disord 2013;28:1544–1551.
60. Mancini M, El-Gohary M, Pearson S, et al. Continuous monitoring of turning in Parkinson's disease: rehabilitation potential. Neurorehabilitation 2015;37:3–10.
61. Galna B, Lord S, Burn DJ, Rochester L. Progression of gait dysfunction in incident Parkinson's disease: Impact of medication and phenotype. Mov Disord 2015;30:359–367.
62. Klucken J, Barth J, Kugler P, et al. Unbiased and mobile gait analysis detects motor impairment in Parkinson's disease. PLoS One 2013;8:e56956.
63. Curtze C, Nutt JG, Carlson-Kuhta P, Mancini M, Horak FB. Levodopa is a double-edged sword for balance and gait in people with Parkinson's disease. Mov Disord 2015;30:1361–1370.
64. Plotnik M, Giladi N, Hausdorff JM. Is freezing of gait in Parkinson's disease a result of multiple gait impairments? Implications for treatment. Parkinsons Dis 2012;2012:459321.
65. Weiss A, Herman T, Giladi N, Hausdorff JM. Objective assessment of fall risk in Parkinson's disease using a body-fixed sensor worn for 3 days. PLoS One 2014;9:e96675.
66. Perez-Lloret S, Negre-Pages L, Damier P, et al. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol 2014;71:884–890.
67. Weiss D, Walach M, Meisner C, et al. Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial. Brain 2013;136:2098–2108.
68. Nieuwboer, A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78:134–140.
69. Bächlin M, Plotnik M, Roggen D, et al. Wearable assistant for Parkinson's disease patients with the freezing of gait symptom. IEEE Trans Inf Technol Biomed 2010;14:436–446.
70. Bächlin M, Plotnik M, Roggen D, Giladi N, Hausdorff JM, Tröster G. A wearable system to assist walking of Parkinson's disease patients. Methods Inf Med 2010;49:88–95.
71. Kwon Y, Park SH, Kim J-W, et al. A practical method for the detection of freezing of gait in patients with Parkinson's disease. Clin Interv Aging 2014;9:1709–1719.
72. Ahlrichs C, Samà A, Lawo M, et al. Detecting freezing of gait with a tri-axial accelerometer in Parkinson's disease patients. Med Biol Eng Comput 2016;54:223–233.
73. Mazilu S, Calatroni A, Gazit E, Mirelman A, Hausdorff JM, Troster G. Prediction of freezing of gait in Parkinson's from physiological wearables: an exploratory study. IEEE J Biomed Heal informatics 2015;19:1843–1854.
74. Acree LS, Longfors J, Fjeldstad AS, et al. Physical activity is related to quality of life in older adults. Heal. Qual Life Outcomes 2006;4:37.
75. Lord S, Godfrey A, Galna B, Mhiripiri D, Burn D, Rochester L. Ambulatory activity in incident Parkinson's: more than meets the eye? J Neurol 2013;260:2964–2972.
76. Speelman AD, van de Warrenburg BP, van Nimwegen M, Petzinger GM, Munneke M, Bloem BR. How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol 2011;7:528–534.
77. van Lummel RC, Walgaard S, Pijnappels M, et al. Physical performance and physical activity in older adults: associated but separate domains of physical function in old age. PLoS One 2015;10:e0144048.
78. Hiorth YH, Larsen JP, Lode K, et al. Impact of falls on physical activity in people with Parkinson's disease. J Parkinsons Dis 2016;6:175–182.
79. Post B, Merkus MP, de Bie R M, de Haan RJ, Speelman JD. Unified Parkinson's Disease Rating Scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? Mov Disord 2005;20:1577–1584.
80. van Uem J, Isaacs T, Lewin A, et al. A viewpoint on wearable technology-enabled measurement of wellbeing and health-related quality of life in Parkinson's disease. J Parkinsons Dis 2016 Mar 10. doi:10.3233/JPD-150740. [Epub ahead of print]
81. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology 2011;77:851–857.
82. van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M. Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord 2013;28:605–611.
83. Kang SK, Murphy RKJ, Hwang S-W, et al. Bioresorbable silicon electronic sensors for the brain. Nature 2016;530:71–76.
84. Espay A, Bonato P, Nahab F, et al. Technology in Parkinson's disease: challenges and opportunities. Mov Disord 2016 Apr 29. doi: 10.1002/mds.26642. [Epub ahead of print] Review.
85. Aarts JW, Vennik F, Nelen WLDM, et al. Personal health communities: a phenomenological study of a new health-care concept. Health Expect 2014;18:2091–2106.
86. European Commission. Technology readiness levels (TRL). Horizon 2020—Work Program. 2014–2015 General Annexes. Brussels: European Commission; 2016.
87. Odin P, Chaudhuri RK, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord 2015;21:1133–1144.